52 results about "Serum cholesterol level" patented technology

Oral compositions, suitable for chewing, comprising a gel-forming polysaccharide isolated from psyllium seed husks and an excipient that is fast dissolving in the oral cavity, provide good aesthetics and acceptable mouthfeel as perceived by the consumer. The oral compositions are useful for normalizing bowel function, reducing human serum cholesterol levels and treatment of other gastrointestinal disorders.

This invention is related to the obtention of a new natural mixture composed of long chain fatty alcohols and long chain fatty acids. This mixture has a relative composition of long chain fatty alcohols and long chain fatty acids that is highly reproducible batch to batch and it is extracted from animal or vegetable wax. This mixture has specific therapeutic properties that support its use as an active component of dietary supplement formulations for reducing serum cholesterol levels (while not decreasing HDL-cholesterol levels) and therefore is effective treating Hypercholesterolemia and reducing the risk of coronary heart disease. This mixture also has been shown to improve male sexual activity. When used in conjunction with salicylic acid the mixture has other therapeutic effects such as inhibiting the atherosclerotic process, platelet hyperaggregability, inhibiting thrombosis and inhibiting inflammation.

A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and / or neurodegenerative disorders in humans and animals. The method comprises administering policosanol and HMG-Co-A reductase inhibitor which together effectively lower serum cholesterol levels. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to HMG-Co-A reductase inhibitor.

Biologically active peptides that are derived from or are similar to sequences of the alphaS1-, alphaS2-, beta- or kapa-casein fractions of milk casein. These peptides are capable of immune modulation and other therapeutic activities, including but not limited to stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, diabetes, hypercholesterolemia, hematological disorders and viral-related diseases.

Plant sterols and plant sterol esters have been shown to be cholesterol-reducing agents in human serum. In the present invention, plant sterols and plant stanols are incorporated into compositions which are dispersible in water by complexing the hydrophobic lipids with water-soluble carbohydrates. The resulting plant sterol-carbohydrate complexes are in an aqueous or powder form which can be readily incorporated with food products in an amount effective to reduce serum cholesterol levels in a human consuming such food product, without adversely modifying the organoleptic properties of the food product.

The invention provides a composition for oral administration comprising a mixture of conjugated linoleic acid (CLA), docosahexaenoic acid “DHA”, vitamin E, vitamin C, vitamin B6, vitamin B12, folic acid, and calcium together with a suitable carrier. These compositions are particularly useful as dietary supplements administered to reduce the risk factors of cardiovascular disease, such as elevated serum cholesterol levels and high blood pressure.

Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors.

The invention provides a composition and a method for lowering blood serum cholesterol levels or for preventing elevated blood serum cholesterol levels, as well as a suitable composition comprising (a) one or more phytosterols and / or phytostanols capable of reducing cholesterol absorption in the intestine and / or one or more soluble fibres capable of inhibiting ileal bile acid absorption, (b) a composition capable of inhibiting cholesterol biosynthesis, and (c) a composition capable of increasing cholesterol metabolism, wherein at least one of compositions (b) and (c) is preferably derived from plants.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

PCT No. PCT / JP98 / 01225 Sec. 371 Date Sep. 24, 1999 Sec. 102(e) Date Sep. 24, 1999 PCT Filed Mar. 23, 1998 PCT Pub. No. WO98 / 42686 PCT Pub. Date Oct. 1, 1998LDL receptor gene expression promoters containing a 1,2,4-triazine derivative of the formula (I): wherein R1 is optionally substituted phenyl or heterocycle; R2 is optionally substituted phenyl, naphthyl, aralkyl, 5- or 6-membered aromatic heterocycle, alkyl, or alkenyl; X is O, S or NR4; R3 is optionally substituted phenyl, naphthyl, aralkyl, 5- to 6-membered aromatic heterocycle, alkyl, cycloalkyl or alkenyl, provided that when X is NR4, then it may form an optionally substituted nitrogen-containing heterocycle, or a pharmaceutically acceptable salt thereof, which can increase the expression dose (the amount of mRNA) of LDL receptor gene, and thus increase the amount of LDL receptor, and reduce the serum cholesterol level, and are useful in the treatment of hyperlipidemia.

The present invention relates to compositions for lowering the serum cholesterol level, which contain (Yucca) extract and / or (Quillaja) extract. The compositions according to the invention, as the human-safe and medically functional compositions, can be used for various purposes comprising the prevention and treatment of cardiovascular disorders such as a hyperlipidemia, and intestinal disorders.

The invention relates to a self-screened Lactobacillus acidophilus SJLH001 (La SJLH001 for short) with probiotic function of regulating blood sugar and cholesterol level and application thereof in probiotic food. The strain has good tolerance to gastrointestinal environment, and has antioxidant, hydrophobic, ultrasonic resistance, reducing power and other in vitro benefits. In vitro and in vivo functional tests showed that La-SJLH001 has significant amylase inhibitory activity and alpha-Glucose glycerase inhibitory activity, and can significantly reduce fasting blood glucose, postprandial blood glucose level, enhance the tolerance of glucose, alleviate the pancreatic islet enlargement, reduce serum cholesterol level, enhance intestinal mucosal protection and other functions. La- SJLH001 has significant hypoglycemic and cholesterol-lowering activities, which makes it widely used in various forms of probiotic foods (such as probiotic tablet candy, probiotic solid drinks, etc.).

Methods, products and compositions are provided which, when administered to a mammal, including humans, raises HDL serum cholesterol levels, while typically also lowering the ratio of LDL to HDL serum cholesterol levels. An effective amount of one or more of a monoterpene, a terpene and a flavonoid are included in the treatment composition.

The present invention is a treatment for reducing serum cholesterol levels. The method involves analyzing a patient's lipid levels to determine a therapeutically sufficient amount of laser energy to apply to reduce a patient's LDL level while preserving his or her HDL level. The therapeutically sufficient amount of laser energy is determined by conducting a standard blood draw from the patient, conducting a lipid panel, and analyzing the results. In the preferred embodiment, a laser having a wavelength of about 635 nm is used to apply a therapeutic amount of laser energy of approximately 6.6 J / cm2, provided over six treatments, each laser treatment two days apart.

The present invention discloses a food supplement with combination of astaxanthin and omega-3. The food supplement is characterized in that the components of the food supplement comprise haematococcus pluvialis powder, perilla seed powder, flax seed powder, schizochytrium limacinum powder and coralline algae powder. The combination of astaxanthin and omega-3 is capable of balancing human immune functions efficiently, enhancing the capability of the body against antiviral infection, inhibiting cancer cell proliferation, curing body injuries rapidly and eliminating vivotoxin. Meanwhile, the growth of bodies, especially bodies of children, is promoted and the physical quality get enhanced. The immune system is enhanced, and the blood circulation of the brain and the whole body is improved. The rise of the blood pressure and blood sugar is suppressed, the brain health is promoted, the cell vitality is improved, the serum cholesterol level is lowered, and the risk of tumor incidence is lowed.

The invention discloses an application of andrographolide C to preparation of a weight-losing food or medicine and an application of a medicine composition composed of the andrographolide C which is used as an active component and a pharmaceutically-acceptable additive to preparation of the weight-losing food or medicine. According to the application, the technical prejudices in the prior art that andrographolide does not have the weight-losing effect are overcome and an application field of the andrographolide C is expanded. A cell experiment shows that the andrographolide C can inhibit the proliferation of 3T3-L1 preadipocytes through an oxidative stress way; the preadipocytes can be effectively prevented from being differentiated to fat cells and lipids in the fat cells are promoted to be decomposed. A mouse experiment shows that the andrographolide C has obvious effects on reducing the growth rate of body mass of a mouse, the food utilization rate and the in-vivo fat, and a dosage dependency relation is formed; the mouse blood glucose level and the serum cholesterol level can be effectively reduced, and the serum free fatty acid level and the oxidation resistance level are improved.

The invention aims to deeply and systematically research active peptide capable of reducing serum cholesterol level by taking whey protein concentrate as a raw material, research a biological enzyme technology and a membrane fractional separation concentration and multiple chromatographic separation and purification technology, prepare whey protein hydrolytic peptide with small molecular weight and a function of reducing cholesterol, and provide theoretical basis and technical support for industrialized production. The invention adopts multiple chromatography to perform separation and purification, so the purity and the cholesterol micelle solubility inhibition ratio of the obtained component are higher; deionized water serves as eluent during gel filtration, so the deionized water is milder compared with the past salt eluent, a separation effect can be achieved well, salt ions are avoided, and health hidden danger is avoided. The obtained product has extremely high safety and no toxic or side effect, has a function of reducing serum cholesterol level, can easily serve as a functional factor to be added into various healthcare foods, can be applied to food and medicine industries and has a good market prospect.

The invention discloses an application of proanthocyanidins in preparing diet food or drug, and discloses an application of a drug composition with proanthocyanidins as an active component and pharmaceutically acceptable additives in preparing the diet food or drug. Mice experiments demonstrate that proanthocyanidins has obvious reduction effects for growth rate of mice body weight, food utilization rate and body fat and presents a dose-dependent relationship, can effectively reduce blood glucose level and serum cholesterol level of the mice, and can increase serum free fatty acid level and oxidation resistant level. Novel medical application and novel application field are developed for proanthocyanidins. Experiments show that the concentration of proanthocyanidins required for treating obesity is relatively low; proanthocyanidins has no side or toxic effect and has the functions of protecting human body blood circulation, enhancing immunity and protecting eyesight, thereby guaranteeing effectiveness of weight reduction and playing a promotion effect for body health.

The present invention provides a fresh bamboo leaf and lotus leaf tea, and a production method thereof. The fresh bamboo leaf and lotus leaf tea is characterized by being composed of the following raw materials: 5-8 parts by weight of lotus leaves; 1-3 parts by weight of fresh bamboo leaves; and 1-2 parts by weight of broadleaf holly leaves. The production method of the fresh bamboo leaf and lotus leaf tea comprises the steps of: washing the lotus leaves, fresh bamboo leaves and broadleaf holly leaves by using tap water or purified water, and drying by baking the materials separately to enable material moisture contents to be 0-5%; pulverizing the dried materials separately by using a pulverizer, sieving through a 40 mesh sieve, and mixing all the materials uniformly in accordance with the above ratio; and packaging the well mixed materials in paper bags by using an automatic packaging machine, and wrapping with aluminum foil bags outside to obtain bagged fresh bamboo leaf and lotus leaf tea. The fresh bamboo leaf and lotus leaf tea of the present invention can lower liquid and remove oil, and significantly reduce serum cholesterol levels of glycerol and cholesterol; and has the effects of regulating blood lipids, preventing obesity and slimming. Because the raw materials lotus leaves, fresh bamboo leaves and broadleaf holly leaves are of medicinal and edible, long-term consumption of the fresh bamboo leaf and lotus leaf tea has no any side effects, but has very obvious health effects.

The invention relates to a xylitol-containing defatted milk powder. The xylitol-containing defatted milk powder contains defatted milk powder and xylitol, and a weight ratio of the defatted milk powder to xylitol is 100:1-2:1. A preparation method of the xylitol-containing defatted milk powder comprises the following steps: 1, mixing the defatted milk powder with xylitol in proportion, and fully stirring to uniformity; and 2, heating to 85-90DEG C, and pasteurizing for 20-25min to obtain the xylitol-containing defatted milk powder. Xylitol is added on the basis of traditional defatted milk powder in the invention, so the xylitol-containing defatted milk powder can improve the hypoglycemia reaction of diabetic patients, has a dual adjustment effect on the blood sugar, can effectively control the diabetes, can eliminate the abnormal phenomenon of the glucose tolerance, can obviously reduce the cholesterol level of serum, and can mitigate the arteriosclerosis symptom.

The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins) are prescribed to lower serum cholesterol levels and reduce the risk of CVD. Despite the success of statins, many patients abandon treatment owing to neuromuscular adverse drug reactions (ADRs). Genome-wide association studies have identified the single-nucleotide polymorphism (SNP) rs4149056 in the SLCO1B1 gene as being associated with an increased risk for statin-induced ADRs.By studying slow-channel syndrome transgenic mouse models, this invention determined that statins trigger ADRs in mice expressing the mutant allele of the rs137852808 SNP in the nicotinic acetylcholine receptor (nAChR) α-subunit gene CHRNA1. Mice expressing this allele show a remarkable contamination of end-plates with caveolin-1 and develop early signs of neuromuscular degeneration upon statin treatment. The invention demonstrates that genes coding for nAChR subunits may contain variants associated with statin-induced ADRs.

The invention relates to the technical field of probiotics, and discloses a probiotic composition with the effects of thrombolysis, blood fat reduction and intestinal flora regulation, and the probiotic composition comprises lactobacillus acidophilus and lactobacillus casei; wherein the lactobacillus acidophilus is prepared from ATCC4356 lactobacillus acidophilus and NS1 lactobacillus acidophilus; the composition also comprises natto freeze-dried powder containing nattokinase. According to the scheme, the lactobacillus acidophilus and the lactobacillus casei are used for regulating and controlling the serum cholesterol level by inhibiting the increase of the content of related biological substances in the lipid metabolism and cholesterol metabolism processes and reducing the content of reductive glutathione; the cholesterol in the intestinal tract is degraded, absorbed and inhibited, so that the content of blood fat is reduced, and the intestinal flora is regulated and controlled by matching with bifidobacteria and directly conveying to the intestinal tract position by using the enteric capsule.

Methods and compounds are disclosed for lowering serum LDL levels or serum cholesterol levels, or for reducing the transport of cholesterol from the gut to the blood or the lymph, based on the observation that a gene known as ABC1 is necessary in order for cholesterol to be transported from the intestinal lumen into the bloodstream. A mutant chicken phenotype, known as the WHAM chicken, characterized by low levels of serum LDL and reduced transport of cholesterol, facilitated the discovery of this function of the ABC1 gene. Techniques which act to inhibit ABC1 activity in the cells of the intestinal wall will result in lower serum cholesterol.

A hypocholesteremic preparation containing at least one phytostenol ester of a conjugated fatty acid having from about 6 to about 24 carbon atoms is disclosed. Methods of reducing serum cholesterol content in a mammal via administration of hypocholesteremic preparations described herein are also disclosed.

The invention discloses low-fat cheddar with high cholesterol-reducing activity and a preparation method thereof. According to the preparation method, lactobacillus plantarum with cholesterol-reducingactivity is used as an auxiliary fermentation agent to be added to low-fat cheddar, inulin is also added, and through maintaining the activity of probiotics, the cheese has good cholesterol-reducingactivity, and simultaneously the defects in the texture and sense qualities of the low-fat cheddar due to reduction of fat are improved. According to the low-fat cheddar disclosed by the invention, the fat content is reduced by 50% or higher compared with the fat content of a normal full-fat group, the texture and mouthfeel are easy to accept by consumers, the viable count of probiotics can be well maintained, the serum total cholesterol (TC) content, triglyceride (TG) content, low-density lipoprotein cholesterol (LDL-C) content and atherogenic index (AI) of a mouse with hyperlipemia are respectively reduced by about 25.57%, 21.62%, 39.11% and 43.81%, and the low-fat cheddar has a certain effect of reducing the serum cholesterol level in vivo and can be used for reducing the risk of occurrence of cardiovascular and cerebrovascular diseases.